Raul Cordoba/X
Jun 29, 2025, 14:28
Raul Cordoba Highlights Study on Performance of CHA2DS2-VASc and HAS-BLED in Predicting Stroke and Bleeding in Atrial Fibrillation and Cancer
Raul Cordoba, Associate Chief at the Department of Hematology at Jiménez Díaz Foundation, shared a post on X:
“Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.
“The CHA2DS2-VASc score had good to modest discrimination in haematological cancer AUC = 0.71 (0.66, 0.76), compared with no-cancer AUC = 0.73 (0.72, 0.74)
HAS-BLED discrimination was poor in haematological cancer AUC = 0.59 (0.55, 0.64), compared with no-cancer AUC = 0.61 (0.60, 0.62)”
Title: Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer
Authors: Alyaa M Ajabnoor, Salwa S Zghebi, Rosa Parisi, Darren M Ashcroft, Corinne Faivre-Finn, Mamas A Mamas, Evangelos Kontopantelis
Read the full article.
Stay updated with Hemostasis Today.
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications